MannKind Corporation presented new clinical and real-world data at ADA 2026 supporting the safety and effectiveness of Afrezza, its inhaled insulin, recently approved for children aged 6 and older with type 1 and type 2 diabetes. Studies showed Afrezza offers comparable glycemic control to rapid-acting insulin analogs with added benefits like improved treatment satisfaction in youth and fewer hypoglycemic events in gestational diabetes. Exploratory data also suggest favorable use with automated insulin delivery systems. These findings reinforce Afrezza as a patient-friendly alternative for diabetes management across various populations, with ongoing research to expand its clinical applications.
Lululemon invested in Syntetica's $30 million Series A funding to support its innovative recycling of Nylon 6 and Nylon 6,6, materials difficult to separate and reuse in textile waste. This move aligns with growing industry demand for sustainable, co...
Ethereum futures long positions among top traders increased by over 3 percentage points across both USDT- and coin-margined markets, indicating a broad-based shift in short-term sentiment. This rise suggests heightened attention on ETH compared to ot...
NVIDIA announced that leading Japanese companies in robotics and manufacturing are adopting its Cosmos, Isaac, Metropolis, and Jetson platforms to accelerate AI-powered intelligent machines across industries. The new Cosmos 3 Edge model enables real-...
Oil prices are rising sharply due to renewed US naval blockades on Iranian shipping and increased tensions in the Strait of Hormuz, a critical oil transit route. Brent crude is holding above $85 and WTI above $80, with forecasts suggesting WTI could ...
The US government announced it will impose a new 25% tariff on Brazilian ethanol starting next Wednesday, accusing Brazil of unfair trade practices. This tariff excludes major Brazilian exports like oil, beef, coffee, and aircraft parts. The move fol...
